CHARLES SCHWAB INVESTMENT MANAGEMENT INC
Position in SGMT — Sagimet Biosciences Inc.
CIK 884546
SAN FRANCISCO, CA
Position in SGMT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$78,375
-$10,425 QoQ
Shares Held
15,000
0.0% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SGMT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $6,185,699,337 across 288 Biotechnology names. SGMT ranks #273 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,920,871 | $857,745,736 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
804,508 | $621,595,061 | |
| 3 | MRNA |
Moderna, Inc.
|
4,734,356 | $240,505,284 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
673,356 | $222,793,299 | |
| 5 | INSM |
INSMED Inc
|
1,069,390 | $174,866,652 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
1,735,476 | $168,775,041 | |
| 7 | INCY |
Incyte Corp
|
1,729,102 | $162,743,080 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,976,094 | $146,744,740 |
All Filings in SGMT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $78,375 | 15,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $88,800 | 15,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $102,900 | 15,000 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $114,300 | 15,000 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $48,900 | 15,000 | Shares | Sole | 2025-09-15 | |
| 2024-03-31 | $281,129 | 51,869 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $68,086 | 12,562 | Shares | Sole | 2024-02-06 | |
| 2023-09-30 | $110,545 | 12,562 | Shares | Sole | 2023-11-08 | |
| No filing history on record for this holder in this stock. | ||||||